Modality
Cell Therapy
MOA
ALKi
Target
HER2
Pathway
Tau
CSU
Development Pipeline
Preclinical
Jul 2020
→ Jul 2026
PreclinicalCurrent
NCT05316211
134 pts·CSU
2020-07→2026-07·Not yet recruiting
NCT06830800
2,094 pts·CSU
2020-12→2025-02·Active
2,228 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-091.1y agoInterim· CSU
2026-07-143mo awayInterim· CSU
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-02-09 · 1.1y ago
CSU
Interim
2026-07-14 · 3mo away
CSU
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05316211 | Preclinical | CSU | Not yet recr... | 134 | NT-proBNP |
| NCT06830800 | Preclinical | CSU | Active | 2094 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |